Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

Core Insights - Exact Sciences Corp. has achieved a significant milestone with its Oncotype DX Breast Recurrence Score® test, as over two million breast cancer patients globally have utilized the test to inform their treatment decisions [1] Company Overview - Exact Sciences Corp. is recognized as a leading provider of cancer screening and diagnostic tests [1] - The Oncotype DX Breast Recurrence Score® test is supported by more than two decades of clinical evidence, establishing it as a global standard-of-care [1]